https://www.selleckchem.com/pr....oducts/avibactam-fre
on-based setting that includes community, regional, and tertiary cancer centers, use of concurrent chemoradiotherapy and trimodality therapy in stage III NSCLC was low despite evidence supporting the potential benefits of these strategies. We aim to develop and validate an effective nomogram prognostic model for patients with typical lung carcinoid tumors using a large patient cohort from the Surveillance, Epidemiology, and End Results (SEER) database. Data from patients with typical lung carcinoid tumors between 2010 and 20
Like
Comment
Share
